CC BY 4.0 · Journal of Health and Allied Sciences NU 2024; 14(02): 149-151
Shaping the AML Treatment Landscape—Modeling a Path through Plenty, Uncertainty, and Paucity
Arran Hodgkinson
1
Mathematical Sciences Research Centre (MSRC), Queen's University Belfast, Belfast, Northern Ireland, United Kingdom
,
Sudhir Tauro
2
Department of Haematology, Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & School of Medicine, Dundee, Scotland, United Kingdom
› Author Affiliations
References
1
Döhner H,
Wei AH,
Appelbaum FR.
et al.
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140 (12) 1345-1377
2
Stone RM,
Mandrekar SJ,
Sanford BL.
et al.
Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017; 377 (05) 454-464
3
Perl AE,
Martinelli G,
Cortes JE.
et al.
Gilteritinib or chemotherapy for relapsed or refractory FLT3 -mutated AML. N Engl J Med 2019; 381 (18) 1728-1740
4
Wang ZY,
Chen Z.
Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111 (05) 2505-2515
5
Erba HP,
Montesinos P,
Kim HJ.
et al;
QuANTUM-First Study Group.
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401 (10388): 1571-1583
6
John MJ,
Kuriakose P,
Smith M,
Roman E,
Tauro S.
The long shadow of socioeconomic deprivation over the modern management of acute myeloid leukemia: time to unravel the challenges. Blood Cancer J 2021; 11 (08) 141
7
Xuan L,
Wang Y,
Huang F.
et al.
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol 2020; 21 (09) 1201-1212
8
Levis MJ,
Hamadani M,
Logan B.
et al;
BMT-CTN 1506/MORPHO Study Investigators.
Gilteritinib as post-transplant maintenance for acute myeloid leukemia with internal tandem duplication mutation of FLT3
. J Clin Oncol 2024; JCO2302474: JCO2302474
9
Kilford PJ,
Chen KF,
Crewe K.
et al.
Prediction of CYP-mediated DDIs involving inhibition: approaches to address the requirements for system qualification of the Simcyp Simulator. CPT Pharmacometrics Syst Pharmacol 2022; 11 (07) 822-832
10 U.S. Food and Drug Administration (FDA). How Modeling Was Used to Support FDA Approval of a Topical Generic Drug Product. Publication date: (14/12/2021). Accessed April 2, 2024 at: https://www.fda.gov/drugs/regulatory-science-action/how-modeling-was-us/ed-support-fda-approval-topical-generic-drug-product
11
Patel N,
Clarke JF,
Salem F.
et al.
Multi-phase multi-layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skin. CPT Pharmacometrics Syst Pharmacol 2022; 11 (08) 1060-1084
12
Grimm D.
EPA scraps plan to end all testing in mammals by 2035. Science 2024; 383 (6680): 248
13
Short NJ,
Zhou S,
Fu C.
et al.
Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol 2020; 6 (12) 1890-1899
14
Ivey A,
Hills RK,
Simpson MA.
et al;
UK National Cancer Research Institute AML Working Group.
Assessment of minimal residual disease in standard-risk AML. N Engl J Med 2016; 374 (05) 422-433
15
Othman J,
Potter N,
Mokretar K.
et al.
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML. Leukemia 2023; 37 (10) 2066-2072
16
Grob T,
Al Hinai ASA,
Sanders MA.
et al.
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2022; 139 (15) 2347-2354
17
Zhao Y,
Chen W,
Yu J.
et al.
TP53 in MDS and AML: biological and clinical advances. Cancer Lett 2024; 588: 216767
18
Hodgkinson A,
Le Cam L,
Trucu D,
Radulescu O.
Spatio-genetic and phenotypic modelling elucidates resistance and re-sensitisation to treatment in heterogeneous melanoma. J Theor Biol 2019; 466: 84-105
19
Hodgkinson A,
Trucu D,
Lacroix M,
Le Cam L,
Radulescu O.
Computational model of heterogeneity in melanoma: designing therapies and predicting outcomes. Front Oncol 2022; 12: 857572
